← Back to GLP-1 DatabaseActive Ingredient semaglutide Drug Class GLP-1 Receptor Agonist Dosage & Administration Injectable Approved Indications Weight Loss FDA Approved June 4, 2021
Wegovy
semaglutide
GLP-1 Receptor AgonistInjectableWeight Loss
Manufacturer: Novo NordiskFDA Approved: June 4, 2021Starting from $1300.00/mo
Overview
Wegovy is a higher-dose semaglutide injection specifically approved for chronic weight management in adults with obesity or overweight.
Clinical Data
Weight Loss Efficacy
~15-17% body weight loss in STEP trials
Common Side Effects
nauseadiarrheavomitingconstipationheadache
Community Side-Effect Reports
User-reported data — not medical advice. Consult your healthcare provider.
Provider Pricing
Ro
$1499.00/mo
✓Consultation included
Hims & Hers
$1599.00/mo
✓Consultation included
Mochi Health
$1300.00/mo
+ consultation fee: $50.00
Found
$1550.00/mo
✓Consultation included
PlushCare
$1600.00/mo
+ consultation fee: $129.00
Calibrate
$1450.00/mo
✓Consultation included